WARF Advances in Health Care | October 2025

WARF ADVANCES
Top licensing prospects from the University of Wisconsin-Madison

Enhancing Immune Checkpoint Blockade Therapy Against Hypoxic Tumors
This improved delivery system is able to penetrate the extracellular matrix and shuttle surface-conjugated protein cages, composed of collagenases and anti-PD-L1 antibodies, to cancerous cells including pancreatic tumors.
Read more

Monitoring Lesion Progression over Multiple Medical Scans
This method for assessing disease progression as revealed by multiple lesions between time-separated scans of a patient assesses overlap between all pairs in the scan sequence and links lesions in different images to maximize overlap globally.
Read more

Lipopeptides and Nanoparticles
UW-Madison researchers have developed a novel lipopeptide-based nanoparticle for efficient delivery of various biomolecules including plasmid DNA, messenger RNA and CRISPR Cas9 ribonucleoprotein.
Read more

Treating Cancer with Targeted Radionuclide Therapy and Dual CAR T Cell Therapy
A team of UW-Madison researchers has developed a new CAR T cell technology to be used in combination with targeted radionuclide treatment for treating solid tumors.
Read more

Enhancing Compliance in Small-Diameter Vascular Grafts
This advanced fabrication method for polytetrafluoroethylene (ePTFE) vascular grafts improves mechanical compliance between the graft and native tissue in small-diameter vascular grafts.
Read more

Activating Appendages to Induce Polypharmacology in Peptide Hormone Analogues
A team of chemists has developed a synthetic peptide that turns a peptide that binds one of the class B GPCRs into a dual agonist.
Read more

Read about more licensing prospects!

Featured UW-Madison Researcher

In the News